Evidence map›Paper›PMID 39852545›Full record

SynthesisMarine drugs2025

Exploring Antibacterial Properties of Marine Sponge-Derived Natural Compounds: A Systematic Review.

Cintia Cristina Santi Martignago, Camila de Souza Barbosa, Homero Garcia Motta, Beatriz Soares-Silva, Erica Paloma Maso Lopes Peres, Lais Caroline Souza E Silva, Mirian Bonifácio, Karolyne Dos Santos Jorge Sousa, Amanda Sardeli Alqualo, Júlia Parisi and 4 more

Abstract readSystematic Review
In one paragraph

Synthesis in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cintia Cristina Santi MartignagoDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Camila de Souza BarbosaDepartment of Microbiology Immunobiology and Parasitology, Paulist School of Medicine, Federal University of São Paulo, São Paulo 04023-062, SP, Brazil.
Homero Garcia MottaDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Beatriz Soares-SilvaDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Erica Paloma Maso Lopes PeresDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Lais Caroline Souza E SilvaDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Mirian BonifácioDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Karolyne Dos Santos Jorge SousaDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Amanda Sardeli AlqualoDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.ORCID 0000-0003-4902-513X
Júlia ParisiDepartment of Physiotherapy, Metropolitan University of Santos (UNIMES), Santos 11045-001, SP, Brazil.ORCID 0000-0002-4325-0638
Olivier JordanInstitute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, 1206 Geneva, Switzerland.ORCID 0000-0003-3752-2198
Ana Claudia Muniz RennoDepartment of Bioscience, Federal University of São Paulo, Santos 11015-020, SP, Brazil.
Anna Caroline Campos AguiarDepartment of Microbiology Immunobiology and Parasitology, Paulist School of Medicine, Federal University of São Paulo, São Paulo 04023-062, SP, Brazil.
Viorica PatruleaInstitute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, 1206 Geneva, Switzerland.ORCID 0000-0003-3906-2041

Funding

Fundação de Amparo a Pesquisa do Estado de Sao Paulo- FAPESP 2019/19708-0Fundação de Amparo a Pesquisa do Estado de Sao Paulo- FAPESP 2021/02974-9Fundação de Amparo a Pesquisa do Estado de Sao Paulo- FAPESP 2023/13928-3
6 · The paper itself

Abstract

The rise in multidrug-resistant (MDR) bacteria has prompted extensive research into antibacterial compounds, as these resistant strains compromise current treatments. This resistance leads to prolonged hospitalization, increased mortality rates, and higher healthcare costs. To address this challenge, the pharmaceutical industry is increasingly exploring natural products, particularly those of marine origin, as promising candidates for antimicrobial drugs. Marine sponges, in particular, are of interest because of their production of secondary metabolites (SM), which serve as chemical defenses against predators and pathogens. These metabolites exhibit a wide range of therapeutic properties, including antibacterial activity. This systematic review examines recent advancements in identifying new sponge-derived compounds with antimicrobial activity, specifically targeting

Indexed as

Anti-Bacterial AgentsBiological ProductsPoriferaAnimalsAquatic OrganismsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsBiological Productsantibacterialmarine spongemultidrug-resistantnatural productP. aeruginosa

Identifiers

PMID39852545
PMCPMC11766522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.